Value of enhanced computed tomography in differentiating small mesenchymal tumours of the gastrointestinal from smooth muscle tumours

Table 2 Comparison of tumour marker levels among the three groups (mean ± SD)

Group	n	CEA (ng/mL)	CA19-9 (ng/mL)	CA-125 (kU/L)	AFP (ng/mL)	CYFRA21-1 (U/mL)
Gastric mesenchymal tumour group	50	1.53 ± 0.24	9.32 ± 2.18	44.34 ± 10.67	5.46 ± 1.18	8.17 ± 1.57
Gastric smooth muscle tumour group	50	0.67 ± 0.15a	8.37 ± 1.81a	41.56 ± 8.74	5.03 ± 0.86	7.44 ± 1.69
Control group	50	1.04 ± 0.18a,b	6.45 ± 1.39a,b	39.67 ± 7.98	5.29 ± 0.74	7.67 ± 1.88
F value		198.507	25.753	2.608	2.100	1.888
P value		0.000	0.000	0.078	0.127	0.156

^aP < 0.05 compared with the gastric mesenchymal tumour group.

^bP < 0.05 compared with the gastric smooth muscle group.

CEA: Carcinoembryonic antigen; CA19-9: Carbohydrate antigen 19-9; CA-125: Carbohydrate antigen 125; AFP: Alpha-fetoprotein; CYFRA21-1: Cytokeratin 19 fragment antigen 21-1.